We are 4-Hydroxypyridine-3-sulfonic acid CAS:51498-37-4 manufacturer and supplier in China, Pls send inquiry of to firstname.lastname@example.org of visit www.nbinno.com our official website should you have any interests
Chemical Name: 4-Hydroxypyridine-3-sulfonic acid
Physical and Chemical Properties:
Density: 1.71 g / cm3
Boiling point: /
Melting point: >300°C
Flash point: /
Refractive index: 1.643
Appearance: white crystalline powder
25kg cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Torasemide CAS:56211-40-6
Related News: The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform.triphenylsilanol CAS:791-31-1;16527-35-8 The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.2-Isocyanatoethylacrylate Retrogenix’s proprietary cell microarray technology provides a fast, accurate and effective solution for determining the primary target and secondary target (off-target) activities of antibodies, proteins, cell therapies, small molecules and viruses.BROMOIODOMETANO CAS:557-68-6 ICIG companies currently employ more than 3,000 people and operate 15 manufacturing facilities in Europe and the United States.“CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.